February 12, 2018
"Emerging technologies such as regenerative medicine will only increase the complexity of the logistics systems that need to be validated, especially as the requirements of the Drug Supply Chain Security act come into force," Mark W. Sawicki, Ph.D., Chief Commercial officer of Cryoport, discusses validation standards and pharmaceutical logistics as biotechnology advances in a recent article in Pharmaceutical Outsourcing. Read more >
Tags: Clinical Trials Logistics, Temperature Controlled Logistics
©2023 Cryoport Systems, LLC. All rights reserved.
A Leap Forward in Standardizing the Regenerative Medicine Supply Chain – What the New ISO 21973 Guidance Means for Cell and Gene Therapy Developers
Cryoport® is a trademark of Cryoport, Inc. and used with permission by Cryoport Systems, LLC